Capricor Therapeutics, Inc. - ROE
CAPR
Price:
$28.38
Market Cap:
$1.30B
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on pioneering transformative cell and exosome-based therapies to treat and prevent a diverse range of diseases and disorders. Their lead therapeutic, CAP-1002, is an allogeneic cell therapy derived from heart tissue. This candidate has successfully completed its Phase III clinical trial for patients afflicted with late-stage Duchenne muscular dystrophy (DMD). CAP-1002 is simultaneously progressing through Phase II clinical testing to address cytokine storm associated with SARS-CoV-2. Beyond CAP-1002, the company is advancing CAP-2003 through preclinical development, aiming to treat trauma-related injuries and medic...[Read more]
Industry
Biotechnology
IPO Date
2007-02-13
Stock Exchange
NASDAQ
Ticker
CAPR
PE Ratio
[-12.23]
ROE
[-59.27%]
Current Ratio
[8.42]
Dividend Yield
[0%]
Enterprise Value
[1.21B]
Dividend History
The ROE as of June 2026 (TTM) for Capricor Therapeutics, Inc. (CAPR) is -59.27%
According to Capricor Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -59.27%. This represents a change of 211.86% compared to the average of -19.01% of the last 4 quarters.
Capricor Therapeutics, Inc. (CAPR) Historical ROE (quarterly & annually)
How has CAPR ROE performed in the past?
The mean historical ROE of Capricor Therapeutics, Inc. over the last ten years is -46.87%. The current -59.27% ROE has changed 26.47% with respect to the historical average. Over the past ten years (40 quarters), CAPR's ROE was at its highest in in the September 2023 quarter at 357.49%. The ROE was at its lowest in in the September 2016 quarter at -10854.65%.
Average
-46.87%
Median
-56.13%
Minimum
-329.12%
Maximum
469.80%
Capricor Therapeutics, Inc. (CAPR) ROE by Quarter and Year
Discovering the peaks and valleys of Capricor Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 285.73%
Maximum Annual ROE = 469.80%
Minimum Annual Increase = -1619.96%
Minimum Annual ROE = -329.12%
| Year | ROE | Change |
|---|---|---|
| 2025 | -34.35% | 23.48% |
| 2024 | -27.82% | -71.79% |
| 2023 | -98.61% | -59.95% |
| 2022 | -246.22% | 285.73% |
| 2021 | -63.83% | 31.80% |
| 2020 | -48.43% | -56.66% |
| 2019 | -111.73% | -66.05% |
| 2018 | -329.12% | -1619.96% |
| 2017 | 21.65% | -95.39% |
| 2016 | 469.80% | -62.30% |
Capricor Therapeutics, Inc. (CAPR) Average ROE
How has CAPR ROE performed in the past?
The current ROE of Capricor Therapeutics, Inc. (CAPR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-53.59%
5-year avg
-94.17%
10-year avg
-46.87%
Capricor Therapeutics, Inc. (CAPR) ROE vs. Peers
How is CAPR’s ROE compared to its peers?
Capricor Therapeutics, Inc.’s ROE is greater than Cabaletta Bio, Inc. (-131.58%), greater than Lexeo Therapeutics, Inc. Common Stock (-47.48%), greater than ProQR Therapeutics N.V. (-86.47%), greater than Entrada Therapeutics, Inc. (-51.22%), greater than Immutep Limited (-69.20%), greater than Allogene Therapeutics, Inc. (-56.45%), greater than Editas Medicine, Inc. (-677.39%), greater than Achieve Life Sciences, Inc. (-193.49%), greater than Arcturus Therapeutics Holdings Inc. (-36.55%), greater than Vanda Pharmaceuticals Inc. (-61.41%),
| Company | ROE | Market cap |
|---|---|---|
| -131.58% | $463.08M | |
| -47.48% | $387.11M | |
| -86.47% | $199.13M | |
| -51.22% | $275.24M | |
| -69.20% | $55.15M | |
| -56.45% | $487.74M | |
| -677.39% | $263.35M | |
| -193.49% | $497.90M | |
| -36.55% | $214.03M | |
| -61.41% | $348.79M |
Build a custom stock screener for Capricor Therapeutics, Inc. (CAPR) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Capricor Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Capricor Therapeutics, Inc. (CAPR) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Capricor Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Capricor Therapeutics, Inc.'s ROE?
How is the ROE calculated for Capricor Therapeutics, Inc. (CAPR)?
What is the highest ROE for Capricor Therapeutics, Inc. (CAPR)?
What is the 3-year average ROE for Capricor Therapeutics, Inc. (CAPR)?
What is the 5-year average ROE for Capricor Therapeutics, Inc. (CAPR)?
How does the current ROE for Capricor Therapeutics, Inc. (CAPR) compare to its historical average?